Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why Is Bausch (BHC) Down 13% Since Last Earnings Report?

2025-05-30
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns

2025-05-29
Key Insights Given the large stake in the stock by institutions, Bausch Health Companies' stock price might be...

Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know

2025-05-27
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +1.5%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025.

3 Reasons to Avoid BLCO and 1 Stock to Buy Instead

2025-05-22
Shareholders of Bausch + Lomb would probably like to forget the past six months even happened. The stock dropped 42.8% and now trades at $11.19. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

Shelton Tactical Credit Fund Q1 2025 Commentary

2025-05-21
In Q1 2025, the Fund posted returns of +1.35% - DEBIX and +1.24% - DEBTX. Read more here.

Bausch Health Announces 2025 Annual Meeting of Shareholder Results

2025-05-14
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed ...

BLCO Q1 Earnings Call: Misses on Profit, Highlights Product Innovation and Tariff Uncertainty

2025-05-14
Eyecare company Bausch + Lomb (NYSE:BLCO) fell short of the market’s revenue expectations in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP loss of $0.07 per share was significantly below analysts’ consensus estimates.

New Strong Sell Stocks for May 13th

2025-05-13
ALTI, AMRK and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2025.

Invesco High Yield Fund Q1 2025 Commentary

2025-05-11
Risk assets were down in the first quarter amid tariff uncertainty. The yield spread between high yield and Treasuries widened. Read more here.

Bausch + Lomb receives CE mark for Luxlife intraocular lens

2025-05-09
The company plans to launch the lens, which supports vision at all distances, in Europe in the coming weeks.